AU2020273154A1 - Plasma kallikrein inhibitors and methods of use thereof in ocular disorders - Google Patents

Plasma kallikrein inhibitors and methods of use thereof in ocular disorders Download PDF

Info

Publication number
AU2020273154A1
AU2020273154A1 AU2020273154A AU2020273154A AU2020273154A1 AU 2020273154 A1 AU2020273154 A1 AU 2020273154A1 AU 2020273154 A AU2020273154 A AU 2020273154A AU 2020273154 A AU2020273154 A AU 2020273154A AU 2020273154 A1 AU2020273154 A1 AU 2020273154A1
Authority
AU
Australia
Prior art keywords
chr
months
administration
drug composition
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020273154A
Other languages
English (en)
Inventor
Yarlagadda Babu
Viral KANSARA
Rick Mcelheny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocryst Pharmaceuticals Inc
Original Assignee
Biocryst Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72750647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2020273154(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocryst Pharmaceuticals Inc filed Critical Biocryst Pharmaceuticals Inc
Publication of AU2020273154A1 publication Critical patent/AU2020273154A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020273154A 2019-04-08 2020-04-08 Plasma kallikrein inhibitors and methods of use thereof in ocular disorders Pending AU2020273154A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962830802P 2019-04-08 2019-04-08
US62/830,802 2019-04-08
PCT/US2020/027287 WO2020210368A1 (en) 2019-04-08 2020-04-08 Plasma kallikrein inhibitors and methods of use thereof in ocular disorders

Publications (1)

Publication Number Publication Date
AU2020273154A1 true AU2020273154A1 (en) 2021-12-02

Family

ID=72750647

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020273154A Pending AU2020273154A1 (en) 2019-04-08 2020-04-08 Plasma kallikrein inhibitors and methods of use thereof in ocular disorders

Country Status (7)

Country Link
US (1) US12589093B2 (https=)
EP (1) EP3953395B1 (https=)
JP (2) JP7668227B2 (https=)
AU (1) AU2020273154A1 (https=)
CA (1) CA3136326A1 (https=)
IL (1) IL287066B1 (https=)
WO (1) WO2020210368A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007104541A2 (en) * 2006-03-16 2007-09-20 Dyax Corp. Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
MX373894B (es) * 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
CA2933900A1 (en) * 2013-12-20 2015-06-25 Georgia Tech Research Corporation Formulations and methods for targeted ocular delivery of therapeutic agents
KR102736869B1 (ko) * 2014-03-07 2024-12-02 바이오크리스트파마슈티컬즈,인코포레이티드 인간 혈장 칼리크레인 저해제
US10428158B2 (en) * 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
JP6824876B2 (ja) * 2014-08-22 2021-02-03 バイオクライスト ファーマシューティカルズ， インコーポレイテッド アミジン誘導体組成物及びそれらの使用
CA3041058A1 (en) 2016-10-31 2018-05-03 Biocryst Pharmaceuticals, Inc. Carbamimidoylphenylcarbamoyl derivatives and pharmaceutical compositions thereof useful as kallikrein inhibithors
AU2018226872A1 (en) * 2017-03-03 2019-09-05 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
JP2020528082A (ja) 2017-07-17 2020-09-17 ロイズマン，キース 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達

Also Published As

Publication number Publication date
JP2025108562A (ja) 2025-07-23
US12589093B2 (en) 2026-03-31
JP7668227B2 (ja) 2025-04-24
US20220160694A1 (en) 2022-05-26
EP3953395A4 (en) 2023-01-18
EP3953395A1 (en) 2022-02-16
CA3136326A1 (en) 2020-10-15
JP2022526999A (ja) 2022-05-27
IL287066B1 (en) 2026-01-01
EP3953395B1 (en) 2026-05-06
IL287066A (en) 2021-12-01
WO2020210368A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
AU2004260645B2 (en) Delivery of a drug via subconjuctival or periocular delivery of a prodrug in a polymeric microparticle
CN102340991B (zh) 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
Schopf et al. Topical ocular drug delivery to the back of the eye by mucus-penetrating particles
EP1802373B1 (en) Carboxy-amido-triazoles for the localized teatment of ocular diseases
NZ725574A (en) Compounds for treating ophthalmic diseases and disorders
Nagai et al. A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure
US20250213541A1 (en) Suspension compositions of multi-target inhibitors
JP7470791B2 (ja) 眼疾患の予防または治療用点眼組成物
JP6861634B2 (ja) 眼疾患を処置するための組成物及び方法
EP3953395B1 (en) Plasma kallikrein inhibitors and methods of use thereof in ocular disorders
EP1867334A1 (en) Method of relieving or avoiding side effect of steroid compound
CA3201534A1 (en) Compounds for treating eye diseases and disorders
Sánchez-Santos et al. Intravitreal bromfenac liposomal suspension (100 μg/0.1 ml). A safety study in rabbit eyes
US20230081539A1 (en) Suprachoroidal delivery of drug particles to reduce toxicity
EP3851097A1 (en) Controlled release formulations
WO2026024285A1 (en) Hydrogel formulations and methods and devices for administration of the same
CN114028421A (zh) 一种使用泊洛沙姆用于治疗眼部疾病的方法
TW202038928A (zh) 多目標抑製劑的懸浮液組合物
HK1221909B (zh) 视网膜脉络膜病症的抑制剂